(Q48008498)

English

Concomitant use of divalproex sodium and lamotrigine in developmentally disabled patients with epilepsy: a retrospective evaluation of efficacy and tolerability.

scientific article published in June 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

Concomitant use of divalproex sodium and lamotrigine in developmentally disabled patients with epilepsy: a retrospective evaluation of efficacy and tolerability. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

1 reference

based on heuristic

inferred from title

1

object named as

Rama Maganti

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

author name string

Barry E. Gidal

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

Roland Shaw

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

Paul Rutecki

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

publication date

1 June 2002

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

Epilepsy Behavior

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

275-279

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

The role of the old and the new antiepileptic drugs in special populations: mental and multiple handicaps

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Intractable epilepsy in a population-based series of mentally retarded children.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Meeting the challenge of epilepsy in persons with multiple handicaps

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A decade of modern epilepsy therapy in institutionalized mentally retarded patients

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of lamotrigine in Lennox-Gastaut and related epilepsy syndromes.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: an open trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Open study evaluating lamotrigine efficacy and safety in add-on treatment and consecutive monotherapy in patients with carbamazepine- or valproate-resistant epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of divalproex-lamotrigine combination therapy in frontal lobe seizures

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adding valproate to lamotrigine: a study of their pharmacokinetic interaction

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage?

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Lamotrigine-associated rash: risk/benefit considerations in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of lamotrigine

1 reference

https://api.crossref.org/works/10.1016%2FS1525-5050%2802%2900028-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1525-5050(02)00028-8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

release_ve56lgxrqbhwjpdm6sn26s4bqa

0 references

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/12662609

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48008498&oldid=2149086857"